Gapping up
In reaction to strong earnings/guidance: FDO +6.9%, CADC +4.6% (ticking higher), HPQ +1.4%.
M&A news: GENZ +0.7% (light volume; higher following reports out overnight that Sanofi is considering increasing its offer for the company).
Select stem cells trading higher: ASTM +5.3%, GERN +4.1%, STEM +3.9%.
Other news: LRAD +23.1% (announces $17.6 million LRAD Systems and maintenance order from a foreign government), YRCW +3.4% (CEO announces he will retire), CRUS +1.4% (Cramer makes positive comments on MadMoney), BA +1.1% (being awarded a $5.297 bln modification to convert the previously awarded advance acquisition contract to a fixed-price-incentive-fee multi-year contract - DoD).
Analyst comments: ISPH +2.1% (initiated with Buy at Jefferies), JBL +1.9% (upgraded to Strong Buy from Buy at Needham), MGM +1.4% (initiated with Market Performs at Wells Fargo), SGEN +1.3% (initiated with Buy at Jefferies), CCL +1.3% (upgraded to Buy from Neutral at Goldman), PLCE +1.3% (initiated with Buy at Goldman), LVS +1.2% (initiated with Market Performs at Wells Fargo), FTE +1.0% (upgraded to Neutral from Underperform at Exane BNP Paribas).
Gapping down
In reaction to disappointing earnings/guidance: MLNK -12.0%, ZZ -11.9%, SMSC -7.7%, MTRX -6.0% (ticking lower).
Select financial related names showing weakness: DB -2.1%, RBS -1.9%, BCS -1.3%, HBC -1.2%, IBN -1.2%, UBS -1.1%, STD -0.7%.
Select metals/mining stocks trading lower: NXG -4.1% (to launch of $135 mln public offering of convertible notes), SLT -3.3%, MT -1.5%, BBL -1.2%, BHP -1.1%, GOLD -1.1%, AU -1.0%, HMY -1.0%, RTP -0.7%.
Other news: GMCR -13.7% (discloses SEC inquiry and overstatement of pretax income), THM -7.3% (announces up to CAD 105,375,000 in equity financings), CHTP -5.2% (announces public offering of common stock), SYT -2.9% (traded lower overseas), ARMH -1.5% (still checking), MFN -0.7% (reports that remediation work on the phase 1 leach pad at the Co's Dolores Mine continues).
Analyst comments: AZN -1.1% (downgraded to Hold from Buy at RBS), FLR -0.7% (with an Underperform at BMO Capital).